1423TiP CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer (mHSPC)
Rana R. McKay(University of California San Diego), Nivedita Agarwal(University of Utah), N. Matsubara(National Cancer Center Hospital East), J.M. Piulats Rodriguez(Institut Català d'Oncologia), Matthew Ryan Smith(Massachusetts General Hospital), T. Todenhöfer, T. Zhang(The University of Texas Southwestern Medical Center), A.V. Balar(Eli Lilly (United States)), Clare Schaverien(Eli Lilly (United States)), S. Sherwood(Eli Lilly (United States)), Elizabeth Johnston(Eli Lilly (United States)), Andrew Lithio(Eli Lilly (United States)), Karim Nacerddine(Eli Lilly (United States)), C. Sweeney(Dana-Farber Cancer Institute)
Cited by 2Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis